Antibody binding to carbonic anhydrase and use thereof
Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
1. An antibody or an antigen-binding fragment thereof, binding to carbonic anhydrase, wherein the antibody or antigen-binding fragment thereof comprises a CDR-H1 comprising SEQ ID NO: 14; a CDR-H2 comprising SEQ ID NO: 15; a CDR-H3 comprising SEQ ID NO: 16; a CDR-L1 comprising SEQ ID NO: 17; a CDR-L2 comprising SEQ ID NO: 18; and a CDR-L3 comprising SEQ ID NO: 19.
2. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof binds to an epitope which is a peptide consisting of 14 to 93 consecutive amino acids containing the amino acid sequence of SEQ ID NO: 3 among amino acid sequence of SEQ ID NO: 5.
3. The antibody or antigen-binding fragment thereof according to claim 2 , wherein the epitope is a peptide consisting of 19 to 93 consecutive amino acids containing the amino acid sequence of SEQ ID NO: 4 among amino acid sequence of SEQ ID NO: 5.
4. The antibody or antigen-binding fragment thereof according to claim 3 , wherein the epitope is a peptide consisting of 14 to 19 consecutive amino acids containing the amino acid sequence of SEQ ID NO: 3 among amino acid sequence of SEQ ID NO: 4.
5. The antibody or antigen-binding fragment thereof according to claim 3 , wherein the epitope is a peptide consisting of 7 to 93 consecutive amino acids containing the amino acid sequence of SEQ ID NOs: 3 or 4.
6. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen binding fragment comprises:
a heavy chain variable region comprising SEQ ID NO: 20; and
a light chain variable region comprising SEQ ID NO: 21.
7. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof is coupled to a labeling agent, a toxin, or an anti-tumor drug.
8. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the labeling agent is selected from the group consisting of a radioisotope, a hapten or a fluorescent, a chromogen, and a dye.
9. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the toxin is selected from the group consisting of a radioisotope, a small molecule, a peptide, and a protein.
10. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the antibody or antigen-binding fragment thereof is coupled with the toxin to form a fusion protein.
11. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the antibody or antigen-binding fragment thereof is partially or completely defucosylated.
12. A pharmaceutical composition, comprising the antibody or antigen-binding fragment thereof according to claim 1 .
13. A composition for detecting a solid cancer that comprises the antibody or antigen-binding fragment thereof according to claim 1 and that the a sample is determined as the solid cancer showing a positive reaction to the antibody or antigen-binding fragment thereof.
14. The composition for detecting a solid cancer according to claim 13 , wherein the antibody or the antigen-binding fragment is coupled to labeling agents.
15. The composition for detecting a solid cancer according to claim 14 , wherein the solid cancer is breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, and liver cancer.
16. The composition for detecting a solid cancer according to claim 15 , wherein the positive reaction is detected by enzyme reaction, fluorescence, luminescence or radiation.